Trials / Active Not Recruiting
Active Not RecruitingNCT05595460
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- RayzeBio, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RYZ101 Dose Level 1 | Dose Level 1 |
| DRUG | RYZ101 Dose Level 2 | Dose Level 2 |
| DRUG | RYZ101 Dose Level 3 | Dose Level 3 |
| DRUG | RYZ101 Dose Level -1 | Dose Level -1 |
| DRUG | Atezolizumab | Atezolizumab |
| DRUG | Carboplatin | Carboplatin |
| DRUG | Etoposide | Etoposide |
Timeline
- Start date
- 2022-10-10
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2022-10-27
- Last updated
- 2026-04-13
Locations
13 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05595460. Inclusion in this directory is not an endorsement.